1. Hepatocyte-Specific Deletion of HIF2α Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation
- Author
-
Beatrice Foglia, G. Villano, Ramy Younes, Emanuele Albano, Salvatore Sutti, Patrizia Pontisso, Riccardo Autelli, Ignazia Tusa, Naresh Naik Ramavath, Chiara Rosso, Elisabetta Rovida, Elisabetta Bugianesi, Erica Novo, Stefania Cannito, Maurizio Parola, Marina Maggiora, and Claudia Bocca
- Subjects
HIF-2α ,NAFLD ,NASH ,hepatocellular carcinoma ,RC799-869 ,Chronic liver disease ,medicine.disease_cause ,0302 clinical medicine ,ERK, extracellular signal-regulated kinase ,Non-alcoholic Fatty Liver Disease ,Nonalcoholic fatty liver disease ,CCN, cyclin ,Original Research ,0303 health sciences ,Fatty liver ,Liver Neoplasms ,Gastroenterology ,Diseases of the digestive system. Gastroenterology ,SB3, SerpinB3 ,mRNA, messenger RNA ,3. Good health ,HIF, hypoxia-inducible factor ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Hepatocyte ,JNK, c-Jun N-terminal kinase ,Q-PCR, quantitative real-time polymerase chain reaction ,Liver cancer ,NASH, nonalcoholic steatohepatitis ,IHC, immunohistochemistry ,Carcinoma, Hepatocellular ,PCNA, proliferating cell nuclear antigen ,Biology ,α-SMA, α-smooth muscle actin ,03 medical and health sciences ,medicine ,Humans ,030304 developmental biology ,CDAA, choline-deficient L-amino acid–defined ,Hepatology ,Cell growth ,Hepatocellular Carcinoma ,medicine.disease ,WT, wild-type ,YAP, Yes-associated protein ,siRNA, small interfering RNA ,CLD, chronic liver disease ,Cancer research ,NAFLD, nonalcoholic fatty liver disease ,Carcinogenesis ,HCC, hepatocellular carcinoma ,DEN, diethylnitrosamine - Abstract
Background & Aims Hypoxia and hypoxia-inducible factors (HIFs) are involved in chronic liver disease progression. We previously showed that hepatocyte HIF-2α activation contributed significantly to nonalcoholic fatty liver disease progression in experimental animals and human patients. In this study, using an appropriate genetic murine model, we mechanistically investigated the involvement of hepatocyte HIF-2α in experimental nonalcoholic steatohepatitis (NASH)-related carcinogenesis. Methods The role of HIF-2α was investigated by morphologic, cellular, and molecular biology approaches in the following: (1) mice carrying hepatocyte-specific deletion of HIF-2α (HIF-2α-/- mice) undergoing a NASH-related protocol of hepatocarcinogenesis; (2) HepG2 cells stably transfected to overexpress HIF-2α; and (3) liver specimens from NASH patients with hepatocellular carcinoma. Results Mice carrying hepatocyte-specific deletion of HIF-2α (hHIF-2α-/-) showed a significant decrease in the volume and number of liver tumors compared with wild-type littermates. These effects did not involve HIF-1α changes and were associated with a decrease of cell proliferation markers proliferating cell nuclear antigen and Ki67. In both human and rodent nonalcoholic fatty liver disease–related tumors, HIF-2α levels were strictly associated with hepatocyte production of SerpinB3, a mediator previously shown to stimulate liver cancer cell proliferation through the Hippo/Yes-associated protein (YAP)/c-Myc pathway. Consistently, we observed positive correlations between the transcripts of HIF-2α, YAP, and c-Myc in individual hepatocellular carcinoma tumor masses, while HIF-2α deletion down-modulated c-Myc and YAP expression without affecting extracellular signal-regulated kinase 1/2, c-Jun N-terminal kinase, and AKT-dependent signaling. In vitro data confirmed that HIF-2α overexpression induced HepG2 cell proliferation through YAP-mediated mechanisms. Conclusions These results indicate that the activation of HIF-2α in hepatocytes has a critical role in liver carcinogenesis during NASH progression, suggesting that HIF-2α–blocking agents may serve as novel putative therapeutic tools., Graphical abstract
- Published
- 2021